Viracta Therapeutics, Inc. (VIRX)
NASDAQ: VIRX · Real-Time Price · USD
0.149
-0.003 (-1.83%)
Nov 21, 2024, 12:02 PM EST - Market open

Company Description

Viracta Therapeutics, Inc., a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide.

Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir.

The company’s Nana-val is in various ongoing clinical trials, including NAVAL-1, an open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors.

Its product pipeline also includes vecabrutinib, a clinical-stage product candidate; and VRx-510, a preclinical product candidate.

The company is headquartered in Cardiff, California.

Viracta Therapeutics, Inc.
Viracta Therapeutics logo
Country United States
Founded 2007
Industry Biotechnology
Sector Healthcare
Employees 40
CEO Mark Rothera

Contact Details

Address:
2533 South Coast Highway 101, Suite 210
Cardiff, California 92007
United States
Phone 858 400 8470
Website viracta.com

Stock Details

Ticker Symbol VIRX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001061027
CUSIP Number 92765F108
ISIN Number US92765F1084
Employer ID 94-3295878
SIC Code 2834

Key Executives

Name Position
Mark Andrew Rothera Chief Executive Officer, President and Director
Dr. Darrel P. Cohen M.D., Ph.D. Chief Medical Officer
Dr. Susan Perrine M.D. Scientific Founder and Consultant
Dr. Ronald J. Berenson M.D. Co-Founder and Consultant
George Hillman Co-Founder
Dr. Thalia Papayannopoulou M.D. Co-Founder
Dr. Robert M. Williams Ph.D. Co-Founder
Dr. Douglas V. Faller M.D., Ph.D. Scientific Founder and Chairman of Scientific Advisory Board
Michael Eric Faerm Chief Financial Officer
Dr. Ayman El-Guindy Chief Scientific Officer

Latest SEC Filings

Date Type Title
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 13, 2024 10-Q Quarterly Report
Nov 13, 2024 8-K Current Report
Nov 6, 2024 8-K Current Report
Aug 14, 2024 10-Q Quarterly Report
Aug 14, 2024 8-K Current Report
Jul 29, 2024 8-K Current Report
Jun 20, 2024 8-K Current Report
May 31, 2024 8-K Current Report
May 14, 2024 8-K Current Report